user

A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.

被引：8
|
作者：
Cohen, Ezra E. W.
Rischin, Danny
Pfister, David G.
Vermorken, Jan Baptist
Zhao, Yufan
Gowda, Hema
Ge, Joy Yang
Jin, Fan
Harrington, Kevin J.
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Peter MacCallum Canc Ctr, East Melbourne, Australia
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Antwerp Univ Hosp, Dept Med Oncol, Edegem, Belgium
[5] Incyte Corp, Wilmington, DE USA
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Inst Canc Res, Sutton, Surrey, England
[8] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS6090
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS6090
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study
    Cho, Byoung Chul
    Brana, Irene
    Cirauqui, Beatriz
    Aksoy, Sercan
    Couture, Felix
    Hong, Ruey-Long
    Miller Jr, Wilson H.
    Chaves-Conde, Manuel
    Teixeira, Margarida
    Leopold, Lance
    Munteanu, Mihaela
    Ge, Joy Yang
    Swaby, Ramona F.
    Hughes, Brett G. M.
    BMC CANCER, 2024, 23 (SUPPL 1)
  • [2] A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
    Lara Jr, Primo N.
    Villanueva, Luis
    Ibanez, Carolina
    Erman, Mustafa
    Lee, Jae Lyun
    Heinrich, Daniel
    Lipatov, Oleg Nikolaevich
    Gedye, Craig
    Gokmen, Erhan
    Acevedo, Alejandro
    Semenov, Andrey
    Park, Se Hoon
    Gafanov, Rustem Airatovich
    Kose, Fatih
    Jones, Mark
    Du, Xiaoqi
    Munteanu, Mihaela
    Perini, Rodolfo
    Choueiri, Toni K.
    Motzer, Robert J.
    BMC CANCER, 2024, 23 (SUPPL 1)
  • [3] KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
    Burtness, B.
    Harrington, K. J.
    Greil, R.
    Soulieres, D.
    Tahara, M.
    De Castro, G., Jr.
    Psyrri, A.
    Rotllan, N. Baste
    Neupane, P. C.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia, R.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Roy, A.
    Cheng, J.
    Jin, F.
    Rischin, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC)
    Posner, Marshall R.
    Wong, Deborah J. L.
    Harrington, Kevin Joseph
    O'Neal, Richard Lee
    Makris, Lukas
    Perdomini, Morgane
    MacIntyre, Susan
    Denker, Andrew
    Saba, Nabil F.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma
    Harrington, K. J.
    William, W. N., Jr.
    Khilnani, A.
    Algazi, A. P.
    ANNALS OF ONCOLOGY, 2020, 31 : S683 - S683
  • [6] Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048
    Yen, C. J.
    Klochikhin, A.
    Cohen, E.
    Vermorken, J.
    Harrington, K.
    Tahara, M.
    Ge, Y.
    Geib, J.
    Jin, F.
    Burtness, B.
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 101
  • [7] Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048
    Klochikhin, A.
    Greil, R.
    Cohen, E.
    Vermorken, J.
    Harrington, K.
    Tahara, M.
    Ge, J. Y.
    Geib, J.
    Jin, F.
    Burtness, B.
    ANNALS OF ONCOLOGY, 2015, 26 : 5 - 5
  • [8] Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
    Psyrri, A.
    Fayette, J.
    Harrington, K.
    Gillison, M.
    Ahn, M. -J.
    Takahashi, S.
    Weiss, J.
    Machiels, J. -P.
    Baxi, S.
    Vasilyev, A.
    Karpenko, A.
    Dvorkin, M.
    Hsieh, C. -Y.
    Thungappa, S. C.
    Segura, P. P.
    Vynnychenko, I.
    Haddad, R.
    Kasper, S.
    Mauz, P. -S.
    Baker, V.
    He, P.
    Evans, B.
    Wildsmith, S.
    Olsson, R. F.
    Yovine, A.
    Kurland, J. F.
    Morsli, N.
    Seiwert, T. Y.
    ANNALS OF ONCOLOGY, 2023, 34 (03) : 262 - 274
  • [9] Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan
    Wang, C. H.
    Lei, H. L.
    Borse, R.
    Chirovsky, D.
    Chien, L.
    Tan, S. C.
    Spiteri, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S1349 - S1349
  • [10] Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study
    Gui, Lin
    Chen, Xinrui
    Xie, Zucheng
    He, Xiaohui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345